Do you want to remove all your recent searches?

All recent searches will be deleted

Like
Watch Later
Share
Add to

Howard Hutchinson, MD, Chief Medical Officer, AstraZeneca

8 years ago257 views

multivu

MultiVu

CRESTOR™ (rosuvastatin) has been approved in nineteen countries within the EU for the prevention of major cardiovascular events in patients who are at high risk of having a first cardiovascular event. This new indication is based on subgroup data from the landmark JUPITER study, which evaluated the impact of rosuvastatin 20 mg on reducing major cardiovascular events in a previously unstudied population. A post-hoc analysis of this subgroup data showed a significant reduction in the combined endpoint of heart attacks, strokes and CV deaths amongst the high risk patients within JUPITER. To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/astrazeneca/43661/

Report this video

Select an issue

Embed the video

Howard Hutchinson, MD, Chief Medical Officer, AstraZeneca
Autoplay
<iframe frameborder="0" width="480" height="270" src="//www.dailymotion.com/embed/video/xd3e67" allowfullscreen allow="autoplay"></iframe>
Add the video to your site with the embed code above